Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Breast Cancer Hormone Therapy Related Musculoskeletal Symptoms

Trial Name: A Randomized Placebo-Controlled Phase III Study of Duloxetine For Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms In Women With Early Stage Breast Cancer.

Protocol ID: S1202



  • Patients must be women with histologically confirmed estrogen receptor (ER) and/or progressive receptor (PgR) positive invasive carcinoma of the breast (Stage I-III) with no evidence of metastatic disease (MD).
  • Patients must have completed mastectomy or breast sparing surgery and must have recovered from all side effects of the surgery.  If patients were treated with chemotherapy and/or radiation therapy, these treatments must be completed at least 28 days prior to study entry.
  • Patients must be post-menopausal.
  • Patients must have aromatase inhibitor (AI) associated musculoskeletal symptoms that began or increased after starting AI therapy.  New musculoskeletal pain must not be due specifically to fracture or traumatic injury.
  • Patients must have no known allergy or hypersensitivity to duloxetine or any of the inactive ingredients in the matching placebo.
  • Patients must meet required laboratory values.

Patients must not have concurrent medical/arthritic disease that could confound or interfere with evaluation of pain or efficacy including: inflammatory arthritis (rheumatoid arthritis, systemic lupus, spondyloarthropathy, psoriatic arthritis, polymyalgia rheumatical) and cancer involving the bone.

Enrollment: • About 294 people will take part in this study at several medical centers.



Taking part in this study may or may not make your health better.  We hope that the information from this study will help doctors learn whether duloxetine reduces joint pain in patients receiving aromatase inhibitors.  This information could help future patients taking aromatase inhibitors.


These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Aspirus Regional Cancer Center Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353, or Langlade Cancer Center Research Nurse Debra Witman @ 715-623-9587.

Created: May 21, 2014

Updated: Oct 16, 2014

« Return to Trials